Emcure Pharmaceuticals to hold physical investor meet in Pune on Sep 4

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Emcure Pharmaceuticals schedules physical investor meet in Pune
  • Event set for September 4, 2026, with institutional investors
  • Company confirms no unpublished price-sensitive info will be shared
  • Disclosure made under SEBI LODR Regulation 30 requirements
powered bylight_fuzz_icon
49806160

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals has scheduled a physical meeting with institutional investors in Pune on September 4, 2026. The company confirmed that no unpublished price-sensitive information will be discussed during the session.

Meeting details

The engagement is part of the company's compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Officials from Emcure will interact directly with a group of institutional investors.

Parameter Details
Event Meeting with group of Institutional Investors
Date September 4, 2026
City Pune
Mode Physical

The schedule is tentative and subject to change due to exigencies on the part of the investors or the company. The disclosure was made pursuant to Para A of Part A of Schedule III of the SEBI regulations.

Historical Stock Returns for Emcure Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.51%-0.42%-5.83%+26.82%+32.47%0.0%

How might Emcure's strategic focus areas discussed in recent earnings calls influence the agenda for this institutional investor meeting?

What impact could the outcomes of this engagement have on Emcure's stock valuation in the short term following the September 4 meeting?

Are there any pending regulatory approvals or clinical trial results for Emcure's pipeline that investors are likely to prioritize during this session?

like17
dislike

Emcure Pharmaceuticals recommends ₹3.60 dividend; AGM on Sept 21

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Emcure Pharmaceuticals schedules 45th AGM for September 21, 2026
  • Board recommends final dividend of ₹3.60 per share for FY26
  • Record date for dividend is set as September 4, 2026
  • Remote e-voting window opens on September 18 and closes on September 20
powered bylight_fuzz_icon
49475711

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals has scheduled its 45th Annual General Meeting (AGM) for Monday, September 21, 2026. The Board of Directors has recommended a final dividend of ₹3.60 per equity share of face value ₹10 each for FY26, representing a 36% payout rate.

The meeting will be held through video conferencing or other audio-visual means, in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India circulars. The event is set to begin at 11:00 am IST. Shareholders holding shares as of the cut-off date, Monday, September 14, 2026, are eligible to attend via the MUFG Intime India Private Limited platform.

Voting Timeline

Remote e-voting will commence on Friday, September 18, 2026, at 9:00 am IST and conclude on Sunday, September 20, 2026, at 5:00 pm IST. Members who have cast their votes via remote e-voting prior to the AGM will not be eligible to vote again during the meeting.

Event Date Time
Remote e-voting begins September 18, 2026 9:00 am
Remote e-voting ends September 20, 2026 5:00 pm
AGM date September 21, 2026 11:00 am

Dividend Details

Upon approval at the AGM, the dividend will be paid to members whose names appear in the Register of Members as at the close of business hours on Friday, September 4, 2026 (Record Date). For shares held in dematerialised form, the dividend will be paid based on beneficial ownership details furnished by the Depositories.

Members are advised to update their KYC details with Depositories and the Registrar and Transfer Agent to receive the final dividend directly through electronic credit. As per the Income Tax Act, dividend income is taxable in the hands of the recipient, and the company will deduct tax at source based on the member's residential status and submitted documents.

Annual Report Availability

The Notice of the 45th AGM and the Annual Report for FY26 are available on the company’s website and the registrar’s portal. The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Newspaper advertisements were published in "Financial Express" and "Loksatta" on August 29, 2026.

Amruta Yangalwar, Company Secretary & Compliance Officer, signed the disclosure on August 29, 2026.

Historical Stock Returns for Emcure Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.51%-0.42%-5.83%+26.82%+32.47%0.0%

How might Emcure's 36% payout rate influence investor sentiment compared to peer companies in the generic pharmaceutical sector?

What strategic capital allocation plans has Emcure outlined for FY27 given the retention of 64% of earnings?

Will the upcoming AGM address any new R&D pipeline milestones or international expansion initiatives for the next fiscal year?

like15
dislike

More News on Emcure Pharmaceuticals

1 Year Returns:+32.47%